The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo. Methods Sequential ultrasound-guided ...

SYK-dependent signals from the pre-BCR then feed into the PI3K pathway through CD19 ... of pre-B-cell proliferation are constitutively expressed in pre-B cells, whereas the expression of important ...

we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal ...

Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs ... Novel clinically relevant therapies based on CD19 tumor expression are shown. CR, complete response; PR, ...

Previously, we have shown that MSC can abrogate plasmablast formation and induce IL-10 + and CD19 + CD38 high CD24 high B cells (11), which are the two main signatures to define ... RNA was isolated ...

We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination in systemic ... This approach allows for the transient, temporal ...

Laura is an assistant editor for The Scientist. She earned her PhD in biomedical sciences from Rush University by studying how circadian rhythms and alcohol affect the gut. View Full Profile. Learn ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech ... of 69% among 13 evaluable patients with diffuse large B-cell lymphoma. Galapagos splits in 2, laying off 40% ...